Loading clinical trials...
Loading clinical trials...
NGS-MRD Evaluation of Antigen-specific T Cells and DC Vaccine Combination Targeting T-cell Acute Lymphoblastic Leukemia
Conditions
Interventions
Antigen-specific T cells CAR-T/CTL and DCvac
Locations
1
China
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China
Start Date
March 15, 2022
Primary Completion Date
December 31, 2024
Completion Date
December 31, 2025
Last Updated
March 15, 2022
NCT04972942
NCT07523555
NCT05376111
NCT05679895
NCT06934382
NCT03690011
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions